Can CBD Help With Cerebral Palsy?

  • A study posted on the Journal of Child Neurology found that CBD treatments significantly reduced cerebral palsy symptoms, such as dystonia, spasticity, sleep disturbances, and pain (1).
  • Prescribed muscle relaxant and anti-convulsant agents have been shown to produce side effects among patients with spasticity (2). Studies demonstrated CBD’s efficacy in reducing spasms led to a decrease in prescription medicine usage (3).
  • A 2019 study found that adults with CP have higher risks of anxiety, insomnia, and depression (4). CBD has been found to possess anxiolytic, sleep-promoting (5), and antidepressant properties (6)
  • Due to inactivity, adults with CP are at risk for hypertension and arthritis (7). Studies have shown that CBD has therapeutic potentials in alleviating high blood pressure (8) and joint pain (9)
  • Studies have shown that children with CP have a high risk of developing seizure disorders (10). Researchers confirmed CBD’s efficacy in treating epileptic seizures, especially in pediatric age (11).

Can CBD Really Help With Cerebral Palsy?

Cerebral palsy (CP) is a congenital condition affecting movements, muscle tone, and body posture. This lifelong condition is diagnosed during infancy or early childhood. 

The primary cause of CP is a brain injury or malformation during neonatal development (12).

Symptoms of cerebral palsy include muscle contractions, spasticity, lack of muscle coordination and balance, involuntary movements, speech delay, learning difficulties, lack of motor skills, and tremors

The types of cerebral palsy depends on the symptoms presented by the individual. 

Spastic cerebral palsy presents with spasms. Axatic cerebral palsy causes trouble with muscle coordination and balance. Dyskinetic cerebral palsy causes involuntary movements.

CP treatment options include surgical procedures, physiotherapy, botox injections, or oral muscle relaxants, such as diazepam, dantrolene, and baclofen (13).

However, muscle relaxants have several side effects, including lightheadedness, lack of muscle control (ataxia), blurred vision, and depression (14)

Moreover, individuals taking muscle relaxants are also at risk of dependency and withdrawal symptoms (15).

Meanwhile, CBD has potential health benefits that may be useful for people with CP. 

CBD vs Spasticity

Currently, there is only one direct study on cannabidiol’s (CBD) therapeutic effects on cerebral palsy symptoms.

The Wolfson Medical Center conducted a clinical trial using CBD and THC (with ratios 20 to 1 and 6 to 1) on children with cerebral palsy (CP)

The study, led by child neurologist, Dr. Luba Blumkin, found that the CBD treatment significantly reduced dystonia, spasticity, sleep difficulties, and pain among CP patients (16).

The clinical trial’s result was supported by other studies on CBD’s efficacy in treating motor disorders

A 2018 study posted in Neurological Disorders mentioned that CBD, with the combination of THC, reduced spasticity in human subjects (17). The authors attributed this hypothesis to CBD’s neuroprotective, anti-inflammatory, and muscle relaxant properties (18)

CP and multiple sclerosis have often been studied together due to similarities in muscle spasms and stiffness symptoms exhibited by the conditions (19). Researchers mention that both conditions cause upper neuron motor dysfunction (20)

A 2015 review indicated that the first-line treatment for both conditions involved muscle relaxant and anti-convulsant agents (21)

However, the authors noted that young children and the elderly displayed adverse effects from the treatments (22)

A study posted by Frontiers in Neurology has noted that CBD treatments improved mobility and reduced spasticity among multiple sclerosis patients. Moreover, CBD’s efficacy significantly reduced the usage of prescription medicines (23)

CBD vs. Cerebral Palsy-Associated Conditions

CBD might also potentially treat other conditions associated with CP.

Studies mention that 23-46% of children with CP experience sleep disturbances. These are usually caused by the child’s immobility and pain (24)

Due to inactivity, adults with CP have higher risks of anxiety, depression (25), cardiovascular disorders, and rheumatoid arthritis (26)

Lastly, studies have shown that children with CP have a high risk of developing seizure disorders. The authors indicated that spastic tetraplegia, a form of cerebral palsy, might be associated with seizures (27)

A study found that CBD reduced depression in human subjects (28). Moreover, studies found that CBD has therapeutic potential in treating high blood pressure (29) and arthritis (30).

A study posted by the Permanente Journal also demonstrated CBD’s efficacy in reducing anxiety scores and improving insomnia among human subjects. The authors observed that among the 72 adults who participated, 79.2% had reduced anxiety, while 66.7% improved their sleep scores (31).

Lastly, researchers confirmed CBD’s efficacy in treating epileptic seizures, especially in pediatric age (32). The epileptic drug, Epidiolex, is the first FDA-approved CBD drug used to treat rare forms of epilepsy (33)

How CBD Oil Works to Help With Cerebral Palsy

The endocannabinoid system (ECS) is studied for its role in maintaining homeostasis in the human body. Studies have acknowledged that activation of cannabinoid receptors, CB1 and CB2, plays a role in modulating functions in the central nervous system (34)

Researchers indicated the high density of cannabinoid receptors in the cerebellum and basal ganglia (areas that control motor function) (35)

Studies showed that CB1 expression plays a role in motor function and spasticity among patients with neurodegenerative disorders (36).  

A study released by Therapeutic Advances in Neurological Disorders has shown that CB1 receptors in the CNS pathways are targets that can deliver antispastic effects. The author added that treatments using cannabinoids might potentially stimulate these targets (37)

Moreover, CB2 expression has been observed to block inflammatory cytokines (proteins released by cells) in the central nervous system (CNS). Studies explained that inflammation in the CNS might be the cause of various symptoms, such as tremors and spasms (38).  

Still, more studies are needed to learn how cannabinoids might influence the ECS and CNS of cerebral palsy patients.

The Pros and Cons of CBD Oil for Cerebral Palsy

The Pros

  • CBD treatments significantly reduced cerebral palsy symptoms, such as dystonia, spasticity, sleep difficulties, and pain (39).
  • CBD’s efficacy in reducing spasms led to decreased usage of muscle relaxant and anti-convulsant agents (40).
  • CBD might reduce anxiety, insomnia (41), and depression in adults with CP (42).  
  • CBD has therapeutic potentials in lowering blood pressure (43) and alleviating joint pain (44)
  • CBD’s efficacy in treating seizures has been proven by studies (45).
  • CBD has been acknowledged to have an excellent safety profile for human consumption (46).  

The Cons

  • CBD may cause side effects, such as drowsiness, loss of appetite, and dry mouth (47).
  • A recent study discovered that high CBD dosage caused hepatotoxicity (liver damage) in rat models (48).
  • CBD is not an approved treatment for CP, and further studies are needed to determine any possible benefits.

How CBD Oil Compares to Alternative Treatments for Cerebral Palsy

The echinacea plant has been traditionally used as an alternative or complementary medicine for CP (49)

Some of the herb’s medicinal claims include improved blood circulation, neural connections, and reduced spasticity. However, until studies prove otherwise, echinacea’s clinical value remains to be seen. 

B12 and omega-3 fatty acid vitamins have been recognized to improve cognitive function. A 2017 study mentioned that early intervention using B12 and omega 3 supplements might improve cognitive functions (50)

CT scans demonstrated this hypothesis following B12 and omega-3 treatments. Children who have hypertonia (muscle stiffness), brain atrophy, and delayed milestones and speech displayed improvements in neuroimaging results (51).

Zingiber officinale (ginger) had been studied for its potential to improve brain functions. A study indicated that ginger root extracts enhanced both attentive and cognitive processing in human subjects (52)

Although CBD has not been shown to improve children’s learning capabilities, it has been acknowledged for its neuroprotective properties (53)

A study posted by the British Journal of Clinical Pharmacology indicated that CBD reduced hypoxia-ischemia (brain damage) and improved brain function in animal models (54)

Moreover, CBD has been observed to possess muscle relaxant properties that might be useful in alleviating hypertonia (55).

How to Choose the Best CBD Oil for Cerebral Palsy

The recommended CBD oil for individuals with CP is the full-spectrum option.

Full-spectrum CBD oil contains all the major cannabinoids in hemp, such as CBD, cannabichromene (CBC), cannabigerol (CBG), cannabinol (CBN), and tetrahydrocannabinol (THC). 

Together, these compounds create a cannabinoid synergy known as the “entourage effect.”

A review published in Frontiers in Plant Science indicated that the entourage effect increased the activity of ECS receptors (56).

The author also explained how CBD, combined with other cannabinoids, displayed high efficacy compared to isolated compounds (57).

Another study demonstrated the entourage effect through a controlled trial on patients with chronic pain (58)

The authors found that THC treatment failed to reduce pain scores significantly. However, treatments containing THC and CBD showed better results (59).

Individuals who want to experience the entourage effect without THC may opt for broad-spectrum CBD. Broad-spectrum contains all the same compounds from full-spectrum except THC

Cannabis products, such as medical marijuana and cannabis oil, are high in THC. Depending on the dispensary, some cannabis products may contain 28% THC (60).

In the United States, CBD products are prohibited from carrying more than 0.3% THC (61)

Individuals who want to take CBD as monotherapy may opt for CBD isolates (99% pure CBD). 

Additional tips to consider before buying CBD:

  • Look for the product’s certificate of analysis (COA) to determine cannabinoid content and safety profile.
  • Do thorough research and check testimonials and reviews of CBD brands.
  • Send inquiries to the customer service department for more information.

CBD Dosage for Cerebral Palsy

More studies are needed to find the appropriate CBD dosage for CP symptoms. However, for any medical condition, experts recommend that first-time CBD users start with a low dose and gradually increase when the body gets used to CBD.

A study posted by the British Journal of Clinical Pharmacology collected thousands of clinical CBD dosing data on various health conditions (62)

The authors indicated that appropriate dosing might range from 1 to 50 milligrams per kilogram a day (63).

Moreover, Pharmacology and Pharmacy shared a study explaining that CBD has a bell-shaped dose-response. The authors observed that a limited CBD dose was enough to produce significant results (64)

A study from Frontiers of Pharmacology supported the bell-shaped dose-response. The authors observed that the 300mg dose reduced anxiety scores better than 150mg and 600mg dosings (65)

However, individuals with CP must practice caution when experimenting with CBD dosage. 

A study released by Molecules found that extremely high CBD doses can cause liver damage in rat models (66)

How to Take CBD Oil for Cerebral Palsy

The most straightforward administration for individuals with CP is through oral or sublingual delivery. 

Oral CBD products include capsules, softgels, and gummies. Individuals may take oral CBD with or without a meal. 

Sublingual delivery methods are available through CBD tinctures. CBD may be taken by using an applicator to put a few drops under the tongue.

Studies have shown that sublingual and oral administration allows plasma concentration to last three to four hours after intake (67).

Moreover, taking CBD through oral and sublingual administration was observed to provide high plasma concentrations when taken with a meal. However, CBD intake during an empty stomach produced faster results (68). However, consuming CBD on a full stomach actually provides maximal absorption.

CBD smoke or vapor inhalation is another way of taking CBD. While it is not recommended for children with CP, it may be an option for adults who have the approval of their licensed physicians. 

The lungs are very efficient in absorbing CBD into the body. There is evidence that vaping or smoking delivered plasma concentrations into the bloodstream in less than 10 minutes (69)

Vaping or smoking CBD may be useful for quick relief from pain, severe spasms, or tremors. However, vaping may present some side effects, such as shortness of breath, chest pain, chemical irritation, and allergic reactions (70)

Conclusion

Cerebral palsy is a lifelong condition. Recommended treatments, alternative, and complementary medicine are only utilized to improve the quality of life

Studies have shown that CBD significantly reduced cerebral palsy symptoms, such as dystonia, spastic movements, sleep difficulties, and pain (71).

CBD’s efficacy in reducing spasms led to a decreased use of muscle relaxant and anti-convulsant agents (72)

Moreover, studies have shown that CBD might be useful in treating medical conditions that may arise concurrently with CP, such as high blood pressure (73), arthritis (74), and seizures (75)

Researchers have shown that CBD might improve mental health due to its sleep-promoting, anxiolytic (76), and antidepressant properties (77).  

Whatever medication is being used, individuals with CP must take the necessary measures to improve mobility and function. Participating in physical therapy, rehabilitation (78), and speech therapy (79) may positively impact their quality of life. 

Individuals with CP must consult with a licensed physician before taking CBD into their daily regimen.


  1. Libzon, S., Schleider, L. B.-L., Saban, N., Levit, L., Tamari, Y., Linder, I., … Blumkin, L. (2018). Medical Cannabis for Pediatric Moderate to Severe Complex Motor Disorders. Journal of Child Neurology, 33(9), 565–571. https://doi.org/10.1177/0883073818773028
  2. Chang, E., Ghosh, N., Yanni, D., Lee, S., Alexandru, D., & Mozaffar, T. (2013). A Review of Spasticity Treatments: Pharmacological and Interventional Approaches. Critical reviews in physical and rehabilitation medicine, 25(1-2), 11–22. https://doi.org/10.1615/CritRevPhysRehabilMed.2013007945
  3. Rudroff, T., & Sosnoff, J. (2018). Cannabidiol to Improve Mobility in People with Multiple Sclerosis. Frontiers in neurology, 9, 183. https://doi.org/10.3389/fneur.2018.00183
  4. Smith, K. J., Peterson, M. D., O’Connell, N. E., Victor, C., Liverani, S., Anokye, N., & Ryan, J. M. (2019). Risk of Depression and Anxiety in Adults With Cerebral Palsy. JAMA neurology, 76(3), 294–300. https://doi.org/10.1001/jamaneurol.2018.4147
  5. Shannon, S., Lewis, N., Lee, H., & Hughes, S. (2019). Cannabidiol in Anxiety and Sleep: A Large Case Series. The Permanente journal, 23, 18–041. https://doi.org/10.7812/TPP/18-041
  6. de Mello Schier AR, de Oliveira Ribeiro NP, Coutinho DS, et al. Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa. CNS Neurol Disord Drug Targets. 2014;13(6):953-960. doi:10.2174/1871527313666140612114838
  7. Nicole Cremer, BS, Edward A. Hurvitz, MD, Mark D. Peterson, PhD, MS. (2017) .University of Michigan, University of Michigan Medical School, Ann Arbor; Department of Physical Medicine & Rehabilitation, University of Michigan, Ann Arbor. Multimorbidity in Middle-Aged Adults with Cerebral Palsy. The American Journal of Medicine. 130, 744.e9-744.e15. Retrieved from https://www.amjmed.com/article/S0002-9343(16)31304-3/pdf
  8. Jadoon, K. A., Tan, G. D., & O’Sullivan, S. E. (2017). A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study. JCI insight, 2(12), e93760. https://doi.org/10.1172/jci.insight.93760
  9. Hendricks, O., Andersen, T. E., Christiansen, A. A., Primdahl, J., Hauge, E. M., Ellingsen, T., Horsted, T. I., Bachmann, A. G., Loft, A. G., Bojesen, A. B., Østergaard, M., Lund Hetland, M., Krogh, N. S., Roessler, K. K., & Petersen, K. H. (2019). Efficacy and safety of cannabidiol followed by an open label add-on of tetrahydrocannabinol for the treatment of chronic pain in patients with rheumatoid arthritis or ankylosing spondylitis: protocol for a multicentre, randomised, placebo-controlled study. BMJ open, 9(6), e028197. https://doi.org/10.1136/bmjopen-2018-028197
  10. A.K. Gururaj, L. Sztriha, A. Bener, A. Dawodu, V. Eapen. (2003). Open Archive. Epilepsy in children with cerebral palsy. DOI:https://doi.org/10.1016/S1059131102002558.
  11. Silvestro, S., Mammana, S., Cavalli, E., Bramanti, P., & Mazzon, E. (2019). Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials. Molecules (Basel, Switzerland), 24(8), 1459. https://doi.org/10.3390/molecules24081459
  12. The Mayo Clinic. Cerebral Palsy Overview. Retrieved from https://www.mayoclinic.org/diseases-conditions/cerebral-palsy/diagnosis-treatment/drc-20354005
  13. Ibid
  14. The Mayo Clinic. Diazepam overview. Retrieved from https://www.mayoclinic.org/drugs-supplements/diazepam-oral-route/side-effects/drg-20072333?p=1
  15. Jones, J. D., Mogali, S., & Comer, S. D. (2012). Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug and alcohol dependence, 125(1-2), 8–18. https://doi.org/10.1016/j.drugalcdep.2012.07.004
  16. Libzon, S., Schleider, L. B.-L., Saban, N., Levit, L., Tamari, Y., Linder, I., … Blumkin, L. (2018). Medical Cannabis for Pediatric Moderate to Severe Complex Motor Disorders. Journal of Child Neurology, 33(9), 565–571. https://doi.org/10.1177/0883073818773028
  17. Zettl, U. K., Rommer, P., Hipp, P., & Patejdl, R. (2016). Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Therapeutic advances in neurological disorders, 9(1), 9–30. https://doi.org/10.1177/1756285615612659
  18. Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses. 2006;66(2):234-246. doi:10.1016/j.mehy.2005.08.026
  19. Yamaguchi, T., Hvass Petersen, T., Kirk, H., Forman, C., Svane, C., Kofoed-Hansen, M., Boesen, F., & Lorentzen, J. (2018). Spasticity in adults with cerebral palsy and multiple sclerosis measured by objective clinically applicable technique. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, 129(9), 2010–2021. https://doi.org/10.1016/j.clinph.2018.07.004
  20. Chang, E., Ghosh, N., Yanni, D., Lee, S., Alexandru, D., & Mozaffar, T. (2013). A Review of Spasticity Treatments: Pharmacological and Interventional Approaches. Critical reviews in physical and rehabilitation medicine, 25(1-2), 11–22. https://doi.org/10.1615/CritRevPhysRehabilMed.2013007945
  21. Ibid
  22. Ibid
  23. Rudroff, T., & Sosnoff, J. (2018). Cannabidiol to Improve Mobility in People with Multiple Sclerosis. Frontiers in neurology, 9, 183. https://doi.org/10.3389/fneur.2018.00183
  24. Dutt, R., Roduta-Roberts, M., & Brown, C. A. (2015). Sleep and Children with Cerebral Palsy: A Review of Current Evidence and Environmental Non-Pharmacological Interventions. Children (Basel, Switzerland), 2(1), 78–88. https://doi.org/10.3390/children2010078
  25. Smith, K. J., Peterson, (2019). Op cit.
  26. Nicole Cremer, (2017). Op cit.
  27. A.K. Gururaj, L. (2003). Op cit.
  28. de Mello Schier AR, de Oliveira Ribeiro NP, Coutinho DS, et al. Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa. CNS Neurol Disord Drug Targets. 2014;13(6):953-960. doi:10.2174/1871527313666140612114838
  29. Jadoon, K. A., (2017). Op cit.
  30. Hendricks, O., (2019). Op cit.
  31. Shannon, S., (2019). Op cit.
  32. Silvestro, S., Mammana, S., Cavalli, E., Bramanti, P., & Mazzon, E. (2019). Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials. Molecules (Basel, Switzerland), 24(8), 1459. https://doi.org/10.3390/molecules24081459
  33. US Food and Drug Administration. FDA Approves First Drug comprised of Cannabidiol. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms
  34. Skaper, S. D., & Di Marzo, V. (2012). Endocannabinoids in nervous system health and disease: the big picture in a nutshell. Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 367(1607), 3193–3200. https://doi.org/10.1098/rstb.2012.0313
  35. Chaves-Kirsten, G. P., Mazucanti, C. H., Real, C. C., Souza, B. M., Britto, L. R., & Torrão, A. S. (2013). Temporal changes of CB1 cannabinoid receptor in the basal ganglia as a possible structure-specific plasticity process in 6-OHDA lesioned rats. PloS one, 8(10), e76874. https://doi.org/10.1371/journal.pone.0076874
  36. Ibid
  37. Zettl, U. K., Rommer, P., Hipp, P., & Patejdl, R. (2016). Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Therapeutic advances in neurological disorders, 9(1), 9–30. https://doi.org/10.1177/1756285615612659
  38. Malfitano, A. M., Proto, M. C., & Bifulco, M. (2008). Cannabinoids in the management of spasticity associated with multiple sclerosis. Neuropsychiatric disease and treatment, 4(5), 847–853. https://doi.org/10.2147/ndt.s3208
  39. Libzon, S., (2018). Op cit.
  40. Rudroff, T., (2018). Op cit.
  41. Shannon, S., (2019). Op cit.
  42. de Mello Schier AR, (2014). Op cit.
  43. Jadoon, K. A., (2017). Op cit.
  44. Hendricks, O., (2019). Op cit.
  45. Silvestro, S., (2019). Op cit.
  46. Iffland, K., & Grotenhermen, F. (2017). An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis and cannabinoid research, 2(1), 139–154. https://doi.org/10.1089/can.2016.0034
  47. Huestis, M. A., Solimini, R., Pichini, S., Pacifici, R., Carlier, J., & Busardò, F. P. (2019). Cannabidiol Adverse Effects and Toxicity. Current neuropharmacology, 17(10), 974–989. https://doi.org/10.2174/1570159X17666190603171901
  48. Ewing LE, Skinner CM, Quick CM, Kennon-McGill S, McGill MR, Walker LA, ElSohly MA, Gurley BJ, Koturbash I. Hepatotoxicity of a Cannabidiol-Rich Cannabis Extract in the Mouse Model. Molecules. 2019 Apr 30;24(9):1694. doi: 10.3390/molecules24091694. PMID: 31052254; PMCID: PMC6539990.
  49. American Botanical Council. Echinacea Purpurea root overview. Retrieved from https://cms.herbalgram.org/expandedE/EchinaceaPurpurearoot.html
  50. K. Yaqob (2017) The positive clinical consequence of early intervention of combined therapy (omega 3 fay acids and b12 vitamin) in children under 5 with variable forms of cerebral palsyArchives of Disease in Childhood;102:A97-A98.
  51. Ibid
  52. Saenghong, N., Wattanathorn, J., Muchimapura, S., Tongun, T., Piyavhatkul, N., Banchonglikitkul, C., & Kajsongkram, T. (2012). Zingiber officinale Improves Cognitive Function of the Middle-Aged Healthy Women. Evidence-based complementary and alternative medicine : eCAM, 2012, 383062. https://doi.org/10.1155/2012/383062
  53. Fernández-Ruiz, J., Sagredo, O., Pazos, M. R., García, C., Pertwee, R., Mechoulam, R., & Martínez-Orgado, J. (2013). Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?. British journal of clinical pharmacology, 75(2), 323–333. https://doi.org/10.1111/j.1365-2125.2012.04341.x
  54. Ibid
  55. Russo E. B. (2008). Cannabinoids in the management of difficult to treat pain. Therapeutics and clinical risk management, 4(1), 245–259. https://doi.org/10.2147/tcrm.s1928
  56. Russo E. B. (2019). The Case for the Entourage Effect and Conventional Breeding of Clinical Cannabis: No “Strain,” No Gain. Frontiers in plant science, 9, 1969. https://doi.org/10.3389/fpls.2018.01969
  57. Ibid
  58. Johnson, J. R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E. D., Potts, R., & Fallon, M. T. (2010). Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of pain and symptom management, 39(2), 167–179. https://doi.org/10.1016/j.jpainsymman.2009.06.008
  59. Ibid
  60. Stuyt E. (2018). The Problem with the Current High Potency THC Marijuana from the Perspective of an Addiction Psychiatrist. Missouri medicine, 115(6), 482–486.
  61. The 2018 United States Farm bill. Retrieved from https://www.usda.gov/farmbill
  62. Millar, S. A., Stone, N. L., Bellman, Z. D., Yates, A. S., England, T. J., & O’Sullivan, S. E. (2019). A systematic review of cannabidiol dosing in clinical populations. British journal of clinical pharmacology, 85(9), 1888–1900. https://doi.org/10.1111/bcp.14038
  63. Ibid
  64. Gallily, Ruth & Yekhtin, Zhannah & Hanus, Lumir. (2015). Overcoming the Bell-Shaped Dose-Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol. Pharmacology & Pharmacy. 06. 75-85. 10.4236/pp.2015.62010.
  65. Zuardi, A. W., Rodrigues, N. P., Silva, A. L., Bernardo, S. A., Hallak, J., Guimarães, F. S., & Crippa, J. (2017). Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life. Frontiers in pharmacology, 8, 259. https://doi.org/10.3389/fphar.2017.00259
  66. Ewing, L. E., (2019). Op cit.
  67. Nadulski T, Sporkert F, Schnelle M, et al. Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract. J Anal Toxicol. 2005;29(8):782-789. doi:10.1093/jat/29.8.782
  68. Ibid
  69. Ohlsson, A., Lindgren, J.‐E., Andersson, S., Agurell, S., Gillespie, H. and Hollister, L.E. (1986), Single‐dose kinetics of deuterium‐labelled cannabidiol in man after smoking and intravenous administration. Biomed. Environ. Mass Spectrom., 13: 77-83. doi:10.1002/bms.1200130206
  70. Shmerling, R.H., Can Vaping Damage Your Lungs? (2019)., Retrieved from https://www.health.harvard.edu/blog/can-vaping-damage-your-lungs-what-we-do-and-dont-know-2019090417734
  71. Libzon, S., (2018). Op cit.
  72. Rudroff, T., (2018). Op cit.
  73. Jadoon, K. A., (2017). Op cit.
  74. Hendricks, O., (2019). Op cit.
  75. Silvestro, S., (2019). Op cit.
  76. Shannon, S., (2019).
  77. de Mello Schier AR, (2014). Op cit.
  78. Das, S. P., & Ganesh, G. S. (2019). Evidence-based Approach to Physical Therapy in Cerebral Palsy. Indian journal of orthopaedics, 53(1), 20–34. https://doi.org/10.4103/ortho.IJOrtho_241_17
  79. National Guideline Alliance (UK). Cerebral palsy in under 25s: assessment and management. London: National Institute for Health and Care Excellence (UK); 2017 Jan. (NICE Guideline, No. 62.) 15, Improving speech, language and communication: speech intelligibility. Available from: https://www.ncbi.nlm.nih.gov/books/NBK533237/
CBD Clinicals is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more